Royalty Pharma Plc

( )
RPRX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 0.82%44.250.9%$1537.37m
JNJJohnson & Johnson -0.60%163.770.7%$982.08m
ABBVAbbVie, Inc. -1.30%106.331.9%$978.80m
MRKMerck & Co., Inc. 0.36%71.940.7%$799.95m
LLYEli Lilly & Co. 0.77%231.861.1%$599.11m
BMYBristol-Myers Squibb Co. -1.27%60.531.0%$545.22m
AZNAstraZeneca Plc 5.29%58.501.0%$274.88m
NVSNovartis AG -0.82%82.800.2%$167.64m
SNYSanofi -1.01%47.890.2%$136.30m
GSKGlaxoSmithKline Plc -0.23%38.840.2%$122.59m
RPRXRoyalty Pharma Plc -4.34%36.830.1%$113.92m
NVONovo Nordisk A/S -1.71%99.680.1%$107.46m
VTRSViatris, Inc. -1.77%13.330.0%$107.28m
RGENRepligen Corp. -0.28%306.056.8%$102.70m
APLSApellis Pharmaceuticals, Inc. -3.36%33.060.0%$93.67m

Company Profile

Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.